JP3384847B2 - アルツハイマー病の治療剤 - Google Patents

アルツハイマー病の治療剤

Info

Publication number
JP3384847B2
JP3384847B2 JP26416393A JP26416393A JP3384847B2 JP 3384847 B2 JP3384847 B2 JP 3384847B2 JP 26416393 A JP26416393 A JP 26416393A JP 26416393 A JP26416393 A JP 26416393A JP 3384847 B2 JP3384847 B2 JP 3384847B2
Authority
JP
Japan
Prior art keywords
alzheimer
disease
dose
nadh
adenine dinucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP26416393A
Other languages
English (en)
Japanese (ja)
Other versions
JPH06192106A (ja
Inventor
イェルク・ビルクマイヤー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JPH06192106A publication Critical patent/JPH06192106A/ja
Application granted granted Critical
Publication of JP3384847B2 publication Critical patent/JP3384847B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP26416393A 1992-09-30 1993-09-28 アルツハイマー病の治療剤 Expired - Fee Related JP3384847B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4232899.3 1992-09-30
DE4232899A DE4232899C2 (de) 1992-09-30 1992-09-30 Verwendung von NADH und NADPH zur Behandlung von Morbus Alzheimer

Publications (2)

Publication Number Publication Date
JPH06192106A JPH06192106A (ja) 1994-07-12
JP3384847B2 true JP3384847B2 (ja) 2003-03-10

Family

ID=6469304

Family Applications (1)

Application Number Title Priority Date Filing Date
JP26416393A Expired - Fee Related JP3384847B2 (ja) 1992-09-30 1993-09-28 アルツハイマー病の治療剤

Country Status (16)

Country Link
US (1) US5444053A (enExample)
EP (1) EP0590321B1 (enExample)
JP (1) JP3384847B2 (enExample)
CN (1) CN1053341C (enExample)
AT (1) ATE162076T1 (enExample)
AU (1) AU664768B2 (enExample)
CA (1) CA2105912C (enExample)
DE (2) DE4232899C2 (enExample)
DK (1) DK0590321T3 (enExample)
ES (1) ES2111104T3 (enExample)
GR (1) GR3026120T3 (enExample)
IL (1) IL106785A (enExample)
MX (1) MX9306049A (enExample)
NO (1) NO303482B1 (enExample)
TW (1) TW231268B (enExample)
ZA (1) ZA936327B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712259A (en) * 1996-04-22 1998-01-27 Birkmayer Pharmaceuticals NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome
US5668114A (en) * 1996-05-08 1997-09-16 Birkmayer Pharmaceuticals NADH and NADPH pharmaceuticals for treating hypertension
EP1190635B1 (en) * 2000-04-28 2004-08-25 Mizuno Corporation Tight-binding structure for footwear
AU2002256422A1 (en) * 2001-05-02 2002-11-11 Blanchette Rockefeller Neurosciences Institute Carbonic anhydrase activators for enhancing learning and memory
US7977049B2 (en) * 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
DE10254995B4 (de) * 2002-11-26 2005-02-10 Juelich Enzyme Products Gmbh Verfahren zur enzymatischen Reduktion von NAD und NADP
US7034011B2 (en) * 2002-12-03 2006-04-25 Kyowa Hakko Kogyo Co., Ltd. Method of stabilizing reduced nicotinamide adenine dinucleotide or reduced nicotinamide adenine dinucleotide phosphate
US20040126751A1 (en) * 2002-12-27 2004-07-01 Birkmayer Jorg G.D. Method of prolonging the life-span of living cells using NADH, NADPH and ADP-ribose
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
TW201207390A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Method for screening agent for antidepressant activity
WO2013009997A1 (en) * 2011-07-12 2013-01-17 Burn-Off, Llc Composition, and method of using the composition, effective for minimizing the harmful effects associated with individuals suffering from alcohol intoxication
EP2574339A1 (de) 2011-09-27 2013-04-03 Johannes Huber Pharmazeutisches Präparat zur Behandlung von NADH-bedingten Erkrankungen
CN103340890B (zh) * 2013-06-08 2016-04-27 苏州人本药业有限公司 Nadph作为制备用于防治脑缺血性中风药物方面的应用
WO2019028877A1 (zh) * 2017-08-11 2019-02-14 邦泰生物工程(深圳)有限公司 一种含有nadh和nadph的组合物及其应用
CN119157897A (zh) * 2023-10-12 2024-12-20 苏州人本药业有限公司 Nadph在制备治疗重性抑郁症、双向抑郁症、脑卒中后抑郁症或神经炎症药物的用途
EP4653001A1 (en) * 2024-05-23 2025-11-26 Universidad Autónoma de Madrid Treatment, diagnosis and/or prognosis of mitochondrial diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814339A (en) * 1986-02-11 1989-03-21 Advanced Biologics, Inc. Treatment for Alzheimer's disease
JP2736103B2 (ja) * 1988-03-01 1998-04-02 ヴァルター・ビルクマイヤー パーキンソン症候群の治療用医薬、およびその製造方法
AT397201B (de) * 1988-06-03 1994-02-25 Birkmayer Joerg Ddr Verwendung des enzym-cofaktors nadph zur herstellung eines arzneimittels
AT397200B (de) * 1988-06-03 1994-02-25 Birkmayer Joerg Ddr Verwendung von selenmethionin zur herstellung eines arzneimittels

Also Published As

Publication number Publication date
DK0590321T3 (da) 1998-09-14
JPH06192106A (ja) 1994-07-12
AU664768B2 (en) 1995-11-30
NO933321D0 (no) 1993-09-17
ZA936327B (en) 1994-03-22
EP0590321A1 (de) 1994-04-06
US5444053A (en) 1995-08-22
EP0590321B1 (de) 1998-01-14
CN1053341C (zh) 2000-06-14
TW231268B (enExample) 1994-10-01
CA2105912C (en) 2000-11-14
CN1089474A (zh) 1994-07-20
NO933321L (no) 1994-04-05
DE59307982D1 (de) 1998-02-19
GR3026120T3 (en) 1998-05-29
MX9306049A (es) 1994-05-31
NO303482B1 (no) 1998-07-20
IL106785A (en) 1997-09-30
ATE162076T1 (de) 1998-01-15
DE4232899C2 (de) 1995-02-23
CA2105912A1 (en) 1994-03-31
DE4232899A1 (de) 1994-03-31
ES2111104T3 (es) 1998-03-01
AU4488793A (en) 1994-04-14
IL106785A0 (en) 1993-12-08

Similar Documents

Publication Publication Date Title
JP3384847B2 (ja) アルツハイマー病の治療剤
US5965571A (en) Cholinesterase inhibitors for treatment of Parkinson's disease
US6191153B1 (en) Use of 2-amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazole as a pharmaceutical composition having an antidepressant activity
JPH02240021A (ja) 抑うつ障害の治療用に適した制御放出製薬組成物
US20020048612A1 (en) GABA substrate and the use thereof for treating cognitive and emotional disorders
US20130059888A1 (en) Medicament for prophylactic and/or therapeutic treatment of alzheimer-type dementia
CA1267094A (en) Therapeutic drug for dementia
Glatt Disulfiram and citrated calcium carbimide in the treatment of alcoholism
US4481206A (en) Spiro succinimide derivative in the treatment of dementia of the Alzheimer type
US7838029B1 (en) Mirtazapine solid dosage forms
EP1307192B1 (en) Candesartan for treating migraine
Madan et al. Attempted suicide following treatment with isoniazid
EP0764025A1 (en) Method and medicine for alleviating jet lag
JPH0569093B2 (enExample)
AU2001274765A1 (en) New use of angiotensin II antagonists
Yew et al. Ciprofloxacin-induced renal dysfunction in patients with mycobacterial lung infections
US5869536A (en) Treatment of hyperkinetic disorders
JPS62267227A (ja) 血中尿酸濃度の低下用医薬
US4188404A (en) Treatment of symptoms of aging
Wendling PTSD can persist months after school shooting
WO2005027968A1 (ja) ダウン症候群治療剤
JP2003277258A (ja) 片頭痛治療剤
WENDLING Project Offers Psychotherapy to Military Families
Moon Nicotine patch plus lozenges best for quitting
Kalant Routine examinations the best approach

Legal Events

Date Code Title Description
LAPS Cancellation because of no payment of annual fees